Skip to content

PRICO: OPTI Target Range

Evaluation of the Impact of a Narrower SpO2 Target Range on Performance of an Automatic FiO2 Control System: a Randomized Study

Status
Completed
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06207994
Acronym
POSTR
Enrollment
11
Registered
2024-01-17
Start date
2024-02-20
Completion date
2025-11-30
Last updated
2026-06-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Neonatal Respiratory Distress, Very Low Birth Weight Infant

Keywords

SpO2 Target Range, pulse oximetry, automatic oxygen control

Brief summary

The aim of the study is to determine if a narrower SpO2 Target Range setting automated control of FiO2 (A-FiO2) is more effective than a wider SpO2 Target Range

Detailed description

A-FiO2 systems have consistently proven to be more effective than manual control. Because it is more precise than manual control, studies of some A-FiO2 systems found small differences in the set target range (shift in the median and width) can optimize the relative performance. Similar studies of the A-FiO2 system (PRICO) used in the investigator's NICU have not been conducted. The standard of practice in the investigator's NICU is to use 4 different target ranges to balance the risk of hypoxia and hyperoxia based on the gestational age vulnerabilities. Based on the studies of other A-FiO2 systems the investigators believe a slightly narrower width target range would be more effective. Therefore, a small systematic study is needed to determine the optimal set target range to achieve the therapeutic goal.

Interventions

DEVICENarrow TR

The width of the PRICO SpO2 TR is set to 3% SpO2.

DEVICEShifted TR

The lower and the upper limits of the PRICO SpO2 TR are increased by 1% SpO2.

Sponsors

Czech Technical University in Prague
Lead SponsorOTHER
University Hospital, Motol
CollaboratorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
SUPPORTIVE_CARE
Masking
NONE

Intervention model description

Subjects will be switched between the standard target range, the narrow target range, and the target range with a higher median every 12 hours. The sequence will be randomized differently for each subject, with a balanced block design such that every 3 days each range is evaluated twice. Once enrolled, each subject will continue in the study with regular changes in averaging time through the course of their need for A-FiO2 or 30 days, whichever is shorter. All other elements of care will be as routinely used.

Eligibility

Sex/Gender
ALL
Age
2 Weeks to No maximum
Healthy volunteers
No

Inclusion criteria

* All VLBW on respiratory support and oxygen requirements after 2 weeks of age in the NICU are eligible after informed consent is obtained.

Exclusion criteria

* Informed consent is not obtained * Recording device for automated control of FiO2 is not available

Design outcomes

Primary

MeasureTime frameDescription
Percent time in the set SpO2 target range30 days of intervention if possiblePercent time in the set SpO2 target range (compliance). Periods with SpO2 higher than the target range with FiO2 = 0.21 will be included in the target range compliance.
Percent time at SpO2 ≤80% and >98%30 days of intervention if possiblePercent time at SpO2 ≤80% and \>98% (safety). Periods with SpO2 higher than 98% with FiO2 = 0.21 will be excluded.

Secondary

MeasureTime frameDescription
Percent time above the set SpO2 target range30 days of intervention if possiblePercent time above the set SpO2 target range. Periods with SpO2 higher than the target range with FiO2 = 0.21 will be excluded from time above the target range.
Percent time below the set SpO2 target range30 days of intervention if possiblePercent time below the set SpO2 target range.

Countries

Czechia

Contacts

PRINCIPAL_INVESTIGATOREkaterina Orlova, MD

Motol University Hospital Prague, Neonatal Unit

PRINCIPAL_INVESTIGATORJan Janota, MD, PhD

Motol University Hospital Prague, Neonatal Unit

PRINCIPAL_INVESTIGATORThomas E Bachman, MSc

Czech Technical University in Prague

PRINCIPAL_INVESTIGATORJana Dornakova, MD

Motol University Hospital Prague, Neonatal Unit

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jun 17, 2026